Many clinical trials have been developed using anti-CD47 (NCT02641002) or bifunctional CD47-PD-1 antibodies (NCT04886271), or anti-SIRPα antibodies (NCT02663518, NCT0399023), with promising and hopeful results for several types of cancer (for more details, please refer to Table 1). This evidence concerns the gene SIRPA and cancer.